Gear­ing up new part­ner­ships, Boehringer gets an op­tion to buy a new play­er in on­colyt­ic virus­es in $230M deal

Boehringer In­gel­heim is ac­tive­ly join­ing the hunt for the next big on­colyt­ic virus pro­gram in the hot and hap­pen­ing can­cer field.

Af­ter back­ing a small start­up round for Vi­raTher­a­peu­tics a lit­tle more than a year ago, the phar­ma com­pa­ny has come back with a $230 mil­lion pack­age deal to part­ner on their work — grab­bing an op­tion in the process to buy the com­pa­ny. And the phar­ma gi­ant says the part­ner­ship is a sign of more deals to come as it gears up new pacts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.